Brandywine Global Investment Management LLC Grows Holdings in Cigna Group $CI

Brandywine Global Investment Management LLC lifted its position in shares of Cigna Group (NYSE:CI) by 5.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 174,534 shares of the health services provider’s stock after acquiring an additional 8,592 shares during the quarter. Brandywine Global Investment Management LLC owned 0.07% of Cigna Group worth $57,697,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. MAI Capital Management lifted its stake in Cigna Group by 1.6% in the 2nd quarter. MAI Capital Management now owns 9,264 shares of the health services provider’s stock valued at $3,062,000 after buying an additional 148 shares in the last quarter. Entropy Technologies LP raised its holdings in shares of Cigna Group by 13.1% during the second quarter. Entropy Technologies LP now owns 9,630 shares of the health services provider’s stock valued at $3,183,000 after acquiring an additional 1,114 shares during the last quarter. Magnetar Financial LLC purchased a new position in shares of Cigna Group in the second quarter valued at approximately $724,000. Swiss National Bank boosted its stake in shares of Cigna Group by 4.6% in the second quarter. Swiss National Bank now owns 820,701 shares of the health services provider’s stock worth $271,307,000 after acquiring an additional 36,300 shares during the last quarter. Finally, Prudential PLC raised its stake in Cigna Group by 63.0% in the 2nd quarter. Prudential PLC now owns 17,116 shares of the health services provider’s stock valued at $5,658,000 after purchasing an additional 6,617 shares during the last quarter. Hedge funds and other institutional investors own 86.99% of the company’s stock.

Insiders Place Their Bets

In related news, insider Brian C. Evanko sold 5,368 shares of the stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $300.00, for a total transaction of $1,610,400.00. Following the completion of the sale, the insider directly owned 51,182 shares of the company’s stock, valued at $15,354,600. This trade represents a 9.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO David Cordani purchased 4,134 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The shares were purchased at an average cost of $241.88 per share, with a total value of $999,931.92. Following the completion of the acquisition, the chief executive officer directly owned 157,935 shares of the company’s stock, valued at $38,201,317.80. This represents a 2.69% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 0.70% of the company’s stock.

Analysts Set New Price Targets

CI has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Cigna Group from $415.00 to $301.00 and set a “buy” rating on the stock in a research note on Monday, November 3rd. The Goldman Sachs Group lowered their price objective on Cigna Group from $370.00 to $330.00 and set a “buy” rating on the stock in a research note on Tuesday, November 4th. UBS Group set a $294.00 price target on Cigna Group in a report on Wednesday, November 12th. Wolfe Research dropped their price objective on shares of Cigna Group from $345.00 to $325.00 and set an “outperform” rating for the company in a report on Wednesday, October 15th. Finally, Jefferies Financial Group restated a “buy” rating and set a $310.00 price objective on shares of Cigna Group in a research report on Monday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Cigna Group has a consensus rating of “Moderate Buy” and a consensus price target of $334.05.

Cigna Group Price Performance

Shares of CI opened at $269.48 on Friday. The firm has a market capitalization of $71.99 billion, a price-to-earnings ratio of 14.71, a PEG ratio of 0.88 and a beta of 0.44. The firm’s fifty day simple moving average is $287.23 and its 200-day simple moving average is $299.57. Cigna Group has a twelve month low of $239.51 and a twelve month high of $350.00. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 0.65.

Cigna Group (NYSE:CI) last announced its quarterly earnings results on Thursday, October 30th. The health services provider reported $7.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.64 by $0.19. The company had revenue of $69.57 billion during the quarter, compared to the consensus estimate of $66.40 billion. Cigna Group had a return on equity of 18.80% and a net margin of 1.92%.Cigna Group’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the previous year, the business earned $7.51 EPS. Cigna Group has set its FY 2025 guidance at 29.600- EPS. Equities analysts forecast that Cigna Group will post 29.77 EPS for the current fiscal year.

Cigna Group Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 18th. Shareholders of record on Thursday, December 4th will be given a dividend of $1.51 per share. This represents a $6.04 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Thursday, December 4th. Cigna Group’s dividend payout ratio (DPR) is presently 26.64%.

Cigna Group Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.